Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues
Clinical trial revenue	$ 340	$ 214	$ 650	$ 379
Grant revenue	126	275	186	486
Total revenues	466	489	836	865
Cost of revenues	306	281	376	508
Gross profit	160	208	460	357
Operating expenses
General and administrative	2,427	3,257	4,407	4,963
Research and development	1,720	1,960	3,147	3,310
Selling and marketing	234	53	521	605
Total operating expenses	4,381	5,270	8,075	8,878
Loss from operations	(4,221)	(5,062)	(7,615)	(8,521)
Other (expense) and income
Non-operating Lawsuit expense	(1,398)		(1,398)
Forgiveness of Paycheck Protection Program loan				300
Interest expense		(2)		(2)
Other expense, net	(5)	54	(121)	100
Total other income and (expenses), net	(1,403)	52	(1,519)	400
Net loss	$ (5,624)	$ (5,010)	$ (9,134)	$ (8,121)
Basic and diluted net loss per share (in Dollars per share)	$ (0.27)	$ (0.26)	$ (0.44)	$ (0.44)
Basic and diluted weighted average common shares outstanding (in Shares)	20,943,897	19,005,007	20,927,640	18,252,219